Does lineage plasticity enable escape from CAR-T cell therapy? Lessons from MLL-r leukemia.

ABSTRACT: The clinical success of engineered, CD19-directed chimeric antigen receptor (CAR) T cells in relapsed, refractory B-cell acute lymphoblastic leukemia (B-ALL) has generated great enthusiasm for the use of CAR T cells in patients with cytogenetics that portend a poor prognosis with conventional cytotoxic therapies. One such group includes infants and children with mixed lineage leukemia (MLL1, KMT2A) rearrangements (MLL-r), who fare much worse than patients with low- or standard-risk B-ALL. Although early clinical trials using CD19 CAR T cells for MLL-r B-ALL produced complete remission in most patients, relapse with CD19-negative disease was a common mechanism of treatment failure. Whereas CD19^neg relapse has been observed across a broad spectrum of B-ALL patients treated with CD

SUBMITTER: Liao W 

PROVIDER: S-EPMC8611617 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature